Calidi Biotherapeutics (CLDI) Shares Outstanding (2021 - 2026)
Calidi Biotherapeutics (CLDI) posted quarterly Shares Outstanding (Entity) of $4302.0 for Q4 2025, down 99.36% year-over-year from $667057.0 in Q4 2024, and down 12.33% quarter-over-quarter from $4907.0 in Q3 2025.
Calidi Biotherapeutics (CLDI) Shares Outstanding (2021 - 2026) Analysis & Trends
Calidi Biotherapeutics' Shares Outstanding (Entity) history runs 5 years deep, the most recent figure standing at $4302.0 for Q4 2025.
- In Q4 2025, Shares Outstanding (Entity) fell 99.36% year-over-year to $4302.0; the TTM figure through Dec 2025 stood at $4302.0 (down 99.36% YoY), while the FY2025 annual figure was $4302.0, down 99.36% from the prior year.
- Shares Outstanding (Entity) for Q4 2025 stood at $4302.0, down from $4907.0 in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $775846.0 in Q3 2024, with the low at $2257.0 in Q1 2025.
- The 5-year median for Shares Outstanding (Entity) is $140719.0 (2023), against an average of $195930.2.
- The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Entity) soared 826.6% in 2024, then sank 99.37% in 2025.
- Calidi Biotherapeutics' Shares Outstanding (Entity) stood at $74081.0 in 2021, then soared by 98.81% to $147281.0 in 2022, then declined by 4.46% to $140719.0 in 2023, then surged by 374.03% to $667057.0 in 2024, then plunged by 99.36% to $4302.0 in 2025.
- Business Quant data shows CLDI's Shares Outstanding (Entity) at $4302.0 in Q4 2025, $4907.0 in Q3 2025, and $2877.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Calidi Biotherapeutics | 1.88 Mn | -2.22 Mn | - | 1.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.42 Mn |
| Dec 31, 2025 | 4,302.00 |
| Sep 30, 2025 | 4,907.00 |
| Jun 30, 2025 | 2,877.00 |
| Mar 31, 2025 | 2,257.00 |
| Dec 31, 2024 | 667,057.00 |
| Sep 30, 2024 | 651,974.00 |
| Jun 30, 2024 | 443,982.00 |
| Mar 31, 2024 | 296,255.00 |
| Dec 31, 2023 | 140,719.00 |
| Sep 30, 2023 | 119,245.00 |
| Jun 30, 2023 | 47,915.00 |
| Mar 31, 2023 | 47,915.00 |
| Dec 31, 2022 | 147,281.00 |
| Sep 30, 2022 | 172,856.00 |
| Jun 30, 2022 | 191,659.00 |
| Mar 31, 2022 | 191,659.00 |
| Dec 31, 2021 | 74,081.00 |